-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On January 14, local time, the World Health Organization (WHO) international guideline development team composed of international experts said that baricitinib is strongly recommended in combination with corticosteroids for severe or critically ill patients with new crowns
The rationale for WHO's strong recommendation is based on moderate-certainty evidence that it improves survival and reduces the need for ventilation, and no increase in adverse effects has been observed
WHO experts noted that baricitinib has similar effects to other arthritis drugs called interleukin-6 (IL-6) inhibitors, so when both are available, they recommend that Choose one based on the experience of the clinician, and it is not recommended to use two drugs at the same time
It is understood that baricitinib is a tyrosine protein kinase (JAK) 1/2 inhibitor discovered by Incyte and licensed to Eli Lilly, which was originally used for one or more disease-modifying antirheumatic drugs ( DMARDs) can be used in combination with methotrexate or other non-biological disease-modifying antirheumatic drugs for the treatment of adults with moderately to severely active rheumatoid arthritis who are ineffective or intolerable
In addition, the domestic pharmaceutical company Nanjing Rucko Pharmaceuticals has completed the BE trial for baricitinib and submitted a generic drug marketing application in August 2021.
In fact, baricitinib has previously been approved for the treatment of patients with new crowns
As for why a rheumatoid arthritis drug can also be used to treat the new crown? According to the report of the "Science and Technology Innovation Board Daily", a medical person said: "This is mainly determined by the action pathway of JAK inhibitors and the chemical structure of baricitinib itself
It is also worth noting that Chengda Pharmaceutical, a domestic pharmaceutical company that will be listed on the Growth Enterprise Market, is the raw material drug provider of baricitinib.
Note: The original text has been deleted
